

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-305

Correspondence



Food and Drug Administration
Center for Drug Evaluation and Research
Office of Drug Evaluation ODE III

FACSIMILE TRANSMITTAL SHEET

DATE: January 24, 2003

To: Charles Vachon, Regulatory, Regulatory Affairs Manager	From: Renee Tyson
Company: Draximage Inc.	Division of Medical Imaging and Radiopharmaceutical Drug Products
Fax number: (514) 694-9295	Fax number: (301) 480-6036
Phone number: (514) 630-7081	Phone number: (301) 827-7510
Subject: Phase 4 Commitment	

Total no. of pages including cover: 1

Comments:

Please send us a fax committing to the following Phase 4 Commitments by 1:00 PM today January 24, 2003.

Document to be mailed: YES NO

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.

If you are not the addressee, or a person authorized to deliver this document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us immediately by telephone at (301) 827-7510. Thank you.



NDA 21-305

Draximage, Inc.
Attention: Richard J. Flanagan, Ph.D.
President
16751 Autoroute TransCanada Highway
Kirkland, Québec
Canada H9H 4J4

Dear Dr. Flanagan:

Please refer to your New Drug Application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (the Act) for Sodium Iodide I¹³¹ Solution, USP.

We also refer to your letter dated October 30, 2002, containing a request for formal dispute resolution, and your letter dated December 11, 2002, received December 12, 2002, which constituted a response to our request for additional information on this matter.

Your appeal requests a reversal of our decision to require a user fee for your NDA for Sodium Iodide I¹³¹ Solution, USP, on the basis that there was no change in the indications or uses sought in the NDA from currently approved products.

I have reviewed the documentation for this matter, and agree that you did not intend to expand upon the approved indication for this product. I accept your offer to delete the reference to adolescent dosage and pediatric use sections from your proposed labeling as this information is no longer required for your application.

Therefore, since your application, submitted under section 505(b)(2) of the Act, does not propose a new indication for a use, a user fee is not required, and your request for a refund will be granted.

Any questions concerning this appeal should be addressed via Ms. Kim Colangelo, Dispute Resolution Project Manager, at (301) 594-5479.

Sincerely,

(See ¹⁵¹ appended electronic signature page)

Janet Woodcock, MD
Director
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Janet Woodcock
1/10/03 01:55:36 PM

ORIGINAL

DRAX  **IMAGE**

RECEIVED

SEP 24 2002

FDR/CDER

By Fax/By Courier

September 23, 2002

Dr. Kyong Kang
Chief, Project Management Staff
Division of Medical Imaging and
Radiopharmaceutical Drug Products
5600 Fishers Lane
Rockville,
Maryland 20857

NEW CORRESP

N-000-C


RE: Application Fees for NDA 21-305 (Sodium Iodide I 131)

Dear Dr. Kang,

Further to your letter dated September 18, 2002, we wish to inform you that a wire transfer was processed on September 19, 2002. We respectfully request that the review and the user fee clock be reactivated.

Should you have any questions or comments, please, do not hesitate to contact us at 514-630-7081, by fax at 514-694-9295 or by e-mail at Cvachon@Draximage.com.

Sincerely yours,



Charles Vachon, M. Sc.
Regulatory Affairs Manager

c.c. Dr. Richard J. Flanagan, President

5 pages redacted from this section of
the approval package consisted of draft labeling